787596-43-4

Basic information

• Product Name: Methyl 2-chloro-5-Methylisonicotinate
• Synonyms: Methyl 2-chloro-5-Methylisonicotinate
• CAS NO: 787596-43-4
• Molecular Formula: C8H8ClNO2
• Molecular Weight: 185.60762
• Mol File: 787596-43-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 2-chloro-5-Methylisonicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-chloro-5-Methylisonicotinate(787596-43-4)
• EPA Substance Registry System: Methyl 2-chloro-5-Methylisonicotinate(787596-43-4)

Safety Data

• Hazardous Substances Data: 787596-43-4(Hazardous Substances Data)

Usage

Description

Methyl 2-chloro-5-methylisonicotinate is a chemical compound with the molecular formula C8H8ClNO2. It is a derivative of isonicotinic acid and is known for its versatile reactivity. Methyl 2-chloro-5-Methylisonicotinate is commonly used in the synthesis of pharmaceuticals and agrochemicals and is a promising building block in the production of various organic compounds, particularly in the field of medicinal chemistry for the development of new drugs with potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
Methyl 2-chloro-5-methylisonicotinate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Methyl 2-chloro-5-methylisonicotinate is used as a building block in the production of agrochemicals, contributing to the creation of compounds that can be utilized in agricultural applications.
It is important to handle Methyl 2-chloro-5-methylisonicotinate with caution and follow proper safety protocols, as it can be hazardous if not handled properly.

Upstream product

• 13061-96-6 dihydroxy-methyl-borane 
• 886365-28-2 methyl 5-bromo-2-chloropyridine-4-carboxylate 
• 67-56-1 methanol 
• 951030-56-1 2-chloro-5-methylisonicotinic acid 
• 75-24-1 trimethylaluminum 
• 79055-62-2 2-chloro-5-methyl-pyridin-4-ylamine 
• 867279-13-8 4-bromo-2-chloro-5-methyl-pyridine 
• 60323-96-8 2-chloro-5-methyl-4-nitropyridine 1-oxide 
• 886365-31-7 5-bromo-2-chloropyridine-4-carboxylic acid 
• 80-48-8 methyl p-toluene sulfonate 
• 1227570-92-4 4-iodo-5-methylpyridin-2(1H)-one 
• 153034-94-7 2-Fluoro-4-iodo-5-methylpyridine 

Relevant articles and documents

Substituted tricyclic compound serving as PRMT5 inhibitor and application of substituted tricyclic compound

The invention belongs to the field of medical chemistry, relates to a substituted tricyclic compound serving as a PRMT5 inhibitor and application of the substituted tricyclic compound, and particularly provides a compound shown as a formula (A) or an isom

PROCESS FOR PREPARING 1-ARYLSULFONYL-PYRROLIDINE-2-CARBOXAMIDE TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST COMPOUNDS AND CRYSTALLINE FORMS THEREOF

The invention relates generally to methods of preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide Transient Receptor Potential channel antagonist compounds of the following structure (I): (I) The invention further relates to solvate and co-crystal polymorphs of crystalline formula (I), and methods of preparation thereof.

APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).